Showing results (41-50 of 190) with videos related to

Sort By:
Pageof 19
Circulation|November 11, 1999
Relation between lesion characteristics and risk with percutaneous intervention in the stent and glycoprotein IIb/IIIa era: An analysis of results from 10,907 lesions and proposal for new classification schemeS G Ellis, V Guetta, D Miller, et al.
Journal of the American College of Cardiology|March 1, 1992
Present status of rescue coronary angioplasty: current polarization of opinion and randomized trialsS G Ellis, F Van de Werf, E Ribeiro-daSilva, et al.
The American Journal of Cardiology|September 11, 1999
Direct myocardial revascularization and angiogenesis--how many patients might be eligible?D Mukherjee, D L Bhatt, M T Roe, et al.
The American Journal of Cardiology|May 1, 1985
Relation between the transmural extent of acute myocardial infarction and associated myocardial contractility two weeks after infarctionS G Ellis, C I Henschke, T Sandor, et al.
The American Journal of Cardiology|May 1, 1996
Importance of case mix during training in interventional cardiologyM J Eisenberg, D A St Claire, K H Mak, et al.
The American Journal of Cardiology|July 1, 1993
Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I)B Pitt, S G Ellis, G B Mancini, et al.
The American Journal of Cardiology|November 15, 2000
Effectiveness of rotational atherectomy of right coronary artery ostial stenosisJ G Motwani, R E Raymond, I Franco, et al.
The American Journal of Cardiology|November 15, 1993
Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study GroupM M Bernardi, R M Califf, N Kleiman, et al.
The Canadian Journal of Cardiology|November 1, 1993
Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin timeF C Nath, D W Muller, U Rosenschein, et al.
Circulation|March 14, 2001
Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) TrialS R Steinhubl, S G Ellis, K Wolski, et al.
Pageof 19